This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Martin, P. L. Articles by Treacy, G. Search for Related Content PubMed PubMed Citation Articles by Martin, P. L. Articles by Treacy, G.

Absence of Adverse Effects in Cynomolgus Macaques Treated with CNTO 95, a Fully Human Anti-v Integrin Monoclonal Antibody, Despite Widespread Tissue Binding

Authors' Affiliations: ¹ Centocor, Radnor, Pennsylvania; ² Pathology Associates, Frederick, Maryland; and ³ Sierra Biomedical, Sparks, Nevada

Requests for reprints: Pauline L. Martin, Department of Toxicology and Investigational Pharmacology, Centocor, Inc., 145 King of Prussia Road, Radnor, PA 19087. Phone: 610-240-8733; Fax: 610-651-6798; E-mail: Pmarti27{at}cntus.jnj.com.

Purpose: CNTO 95 is a fully human anti-v integrin monoclonal antibody that inhibits macaque and rodent angiogenesis and inhibits human tumor growth in rodents. The purpose of these studies was to evaluate the preclinical safety of long-term administration of CNTO 95 in cynomolgus macaques.

Experimental Design: The in vitro binding profiles of CNTO 95 to human and macaque tissues and the in vivo binding to macaque tissues was evaluated by immunohistochemistry. The preclinical safety of CNTO 95 (10 and 50 mg/kg, i.v.) was evaluated in macaques treated once per week for up to 6 months. Safety was evaluated by clinical observations, ophthalmic and physical examinations (including heart rate, blood pressure, and electrocardiogram), clinical pathology (including coagulation parameters), and comprehensive anatomic pathology. The effect of CNTO 95 (50 mg/kg, i.v.) on incisional wound healing was evaluated in macaques.

Results: The tissue binding studies showed that CNTO 95 bound with mild to moderate intensity to macaque and human endothelial cells, epithelial cells, and vascular smooth muscle cells in most normal tissues examined. CNTO 95 showed strong to intense staining to the positive control tissue, human placenta. Despite the widespread binding to normal tissues, treatment of cynomolgus macaques with CNTO 95 produced no signs of toxicity and no histopathologic changes in any of the tissues examined (including ovaries and bone growth plates). CNTO 95 did not impair wound healing.

Conclusion: These studies show that CNTO 95 is safe and, unlike some other angiogenesis inhibitors, does not seem to inhibit normal physiologic angiogenesis.

This article has been cited by other articles:

				S. Ning, J. A. Nemeth, R. L. Hanson, K. Forsythe, and S. J. Knox Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo Mol. Cancer Ther., June 1, 2008; 7(6): 1569 - 1578. [Abstract] [Full Text] [PDF]

				R. J. Santulli, W. A. Kinney, S. Ghosh, B. L. DeCorte, L. Liu, R. W. A. Tuman, Z. Zhou, N. Huebert, S. E. Bursell, A. C. Clermont, et al. Studies with an Orally Bioavailable {alpha}V Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 894 - 901. [Abstract] [Full Text] [PDF]